ライフサイエンスコーパス: cystadenoma

1 normal ovarian surface epithelium and benign cystadenoma.

2 as, endolymphatic sac tumors, and epididymal cystadenomas.

3 ignant potential and carcinomas but not with cystadenomas.

4 ents underwent surgery for 14 benign (serous cystadenomas = 10, Hamoudi = 2, lymphoepithelial = 1, si

5 denoma 9, borderline 9, cancer 4), 23 serous cystadenomas, 13 other pancreatic cysts, 27 pancreatic e

6 Of the 19 patients with biliary cystadenoma, 16 (84.2 %) were female.

7 oup were IPMN without invasive cancer (30%), cystadenoma (17%), and pancreatic ductal adenocarcinoma

8 hronic pancreatitis (24%), benign pancreatic cystadenoma (22%), pancreatic adenocarcinoma (18%), neur

9 lasms of the pancreas, 54 were classified as cystadenomas, 23 as noninvasive proliferative cystic muc

10 y 100% incidence of multiple bilateral renal cystadenomas, 50% incidence of liver hemangiomas, and 32

11 pseudopapillary neoplasms(12%), and mucinous cystadenomas (6%).

12 Biliary cystadenoma, a benign hepatic tumor arising from Von Mey

13 ncy and the development of pancreatic serous cystadenomas, a tumor type associated with PJS.

14 of BRAF and KRAS occur in the epithelium of cystadenomas adjacent to SBTs and strongly suggest that

15 Tsc1 heterozygotes develop kidney cystadenomas and liver hemangiomas at high frequency, bu

16 ovarian cancers compared with benign ovarian cystadenomas and that gankyrin regulates FSH upregulatio

17 seven were confirmed benign at surgery (four cystadenomas and three inflammatory), one had a benign p

18 Nineteen patients with intrahepatic biliary cystadenomas and two patients with biliary cystadenocarc

19 ovaries: There was one dermoid, one mucinous cystadenoma, and two adenofibromas.

20 d in both the cell lines and Tsc mouse renal cystadenomas, and ectopic expression of PDGFRbeta in Tsc

21 Paraovarian cystadenomas are cystic masses that usually contain one

22 Large (>4 cm) serous cystadenomas are more likely to be symptomatic.

23 h many cysts, such as pseudocysts and serous cystadenomas, are benign and can be monitored clinically

24 the first documentation of a DALM (mucinous cystadenoma) arising in the appendix in the setting of U

25 Biliary cystadenoma (BCA) and biliary cystadenocarcinoma (BCAC)

26 re we show that a subset of cultured ovarian cystadenoma cells expressing SV40 large T-antigen, which

27 d to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model.

28 alized ovarian surface epithelia and ovarian cystadenoma cells showed much higher similarity to prima

29 a subset of SV40 large T-antigen-expressing cystadenoma cells.

30 ancers, ovarian surface epithelia cells, and cystadenoma cells.

31 and two of four neoplasms (50%) (all serous cystadenomas) demonstrated T2 dark spots.

32 The renal cystadenomas develop from intercalated cells of the cort

33 detected in SBTs were also identified in the cystadenoma epithelium adjacent to the SBTs in six (86%)

34 As compared to SBTs, the cystadenoma epithelium, like ovarian surface epithelium,

35 es of histopathologically proved paraovarian cystadenomas from January 1993 through December 1996 in

36 y genetic background, with fewer large renal cystadenomas in the outbred Black Swiss background and m

37 atients had pathologically confirmed biliary cystadenomas, including one with a biliary cystadenocarc

38 multifocal colon cancer, and an appendiceal cystadenoma is described.

39 lecular genetic studies suggest that ovarian cystadenomas, low malignant potential tumors, and carcin

40 Among O-glycans from an ovarian cystadenoma mucin, isomeric oligosaccharide sequences, s

41 Biliary cystadenoma must be recognized and treated differently t

42 = 21; 3%), cystadenocarcinoma (n = 14; 2%), cystadenoma (n = 25; 4%), and other (n = 45; 7%).

43 Chronic pancreatitis (n = 7), serous cystadenomas (n = 5), benign mucinous cystic neoplasms (

44 papillary mucinous neoplasms (n=15), serous cystadenomas (n=12), or pseudocysts (n=9), with confirma

45 Neoplasms were reclassified as mucinous cystadenomas, noninvasive proliferative mucinous cystic

46 total of 106 patients presenting with serous cystadenoma of the pancreas from 1976-2004 were identifi

47 ine whether surgical enucleation of mucinous cystadenoma of the pancreas is a safe and adequate opera

48 Serous cystadenoma of the pancreas is the most common benign pa

49 mas, endolymphatic-sac tumors, and papillary cystadenomas of the epididymis and broad ligament.

50 Mucinous cystadenomas of the pancreas are premalignant cystic les

51 rience suggests that enucleation of mucinous cystadenomas of the pancreas can be performed safely and

52 ween January 1990 and June 1997, 36 mucinous cystadenomas of the pancreas were resected at The Johns

53 ine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive adnexal organs.

54 reviewed to confirm the diagnosis of biliary cystadenoma or biliary cystadenocarcinoma by 2 GI pathol

55 s with IPMN, but not in patients with serous cystadenoma or controls.

56 findings of surgically excised lesions were cystadenoma or cystadenofibroma (n = 14; 11 serous, thre

57 Fourteen paraovarian cystadenomas or cystadenofibromas were identified in 14

58 eoplasms) from benign cystic lesions (serous cystadenomas+pseudocysts) with a 78% sensitivity at 80%

59 ors, we recommend resection for large serous cystadenomas regardless of the presence or absence of sy

60 Many patients with benign serous cystadenoma (SCA) of the pancreas will undergo resection

61 eveloped a novel pancreatic neoplasm, serous cystadenoma (SCA), presenting as large epithelial tumors

62 h of the major neoplastic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neop

63 Ten serous cystadenomas served as negative controls.

64 Serous cystadenomas, solid and cystic papillary (Hamoudi) tumor

65 neoplasms, mucinous cystic neoplasms, serous cystadenomas, solid pseudopapillary neoplasms, cystic va

66 be distinguished from serous lesions (serous cystadenomas) that are nearly always benign.

67 n both SBTs and the adjacent epithelium from cystadenomas, the presumed precursor of SBTs.

68 ation about the imaging findings for biliary cystadenoma to reduce the demonstrated delay in appropri

69 Renal lesions progressed from cysts through cystadenomas to solid carcinomas.

70 result, management for patients with serous cystadenomas varies widely in current practice.

71 are potentially malignant and that mucinous cystadenomas, when completely removed, are biologically

72 DLX4 was not detected in normal ovary and cystadenomas, whereas its expression in ovarian carcinom